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We conducted a systematic analysis to determine the reason for the apparent disparity of success of immunotherapy
between clinical and experimental cancers. To do this, we performed a search of PubMed using the keywords
“immunotherapy” AND “cancer” for the years of 1980 and 2010. The midspread of experimental tumors used in all the
relevant literature published in 2010 were between 0.5–121 mm
3 in volume or had grown for four to eight days. Few
studies reported large tumors that could be considered representative of clinical tumors, in terms of size and duration of
growth. The predominant effect of cancer immunotherapies was slowed or delayed outgrowth. Regression of tumors
larger than 200 mm
3 was observed only after passive antibody or adoptive T cell therapy. The effectiveness of other types
of immunotherapy was generally scattered. By comparison, very few publications retrieved by the 1980 search could
meet our selection criteria; all of these used tumors smaller than 100 mm
3, and none reported regression. In the entire
year of 2010, only 13 used tumors larger than 400 mm
3, and nine of these reported tumor regression. Together, these
results indicate that most recent studies, using many diverse approaches, still treat small tumors only to report slowed or
delayed growth. Nevertheless, a few recent studies indicate effective therapy against large tumors when using passive
antibody or adoptive T cell therapy. For the future, we aspire to witness the increased use of experimental studies
treating tumors that model clinical cancers in terms of size and duration of growth.
Introduction
Clinical success of cancer immunotherapy has been frustratingly
evasive. Successful experimental therapies have rarely led to
effective clinical therapies, and reported experimental successes are
largely limited to therapies against small tumors. Rejection of
large, established disease is rare. Summarizing three decades of
studies on immunity to cancer, William Woglom concluded in
1929 that immunotherapy is futile against an established tumor,
and “nothing may accordingly be hoped for at present in respect
to a successful therapy from this direction.”
1 Eighty-two years
later, the outlook is not quite so grim, as future successes can be
expected to evolve from clinically relevant experimental models.
The difficulty of combating an established disease is partly
founded in fundamental Darwinian principles. Statistically, the
cellular heterogeneity within a tumor becomes relevant when the
tumor accumulates one billion (10
9) cancer cells, in man and in
mouse, equivalent to a tumor with a diameter of 1 cm.
2,3 At this
point, the accumulation of cancer cell variants results in miniscule
probability that all cancer cells are susceptible to a single
chemotherapeutic agent.
2,3 This statement is based on models of
chemotherapy, but there is nothing to suggest that immunothera-
pies cannot be modeled in the same way; for example, antigen-loss
variants can be considered analogous to drug-resistant mutants.
The relevant variables that could be considered are innumerable,
but the nature of the problem is fundamentally the same in
both cases.
Apart from matters of size and cell number, the physiology of
tumors is also a critical feature in cancer therapy. Indeed, the
growth and establishment of a transplanted tumor is distinct
from the development of an autochthonous cancer. Histological
examination reveals that the early growth of a transplanted tumor
following inoculation is marked by substantial inflammation,
necrosis, and only a thin rim of viable cancer cells.
4 But the
formation of an established billion cell mass of one centimeter
diameter renders a tumor histologically indistinguishable from
those presented clinically.
4 At this time, the tumor presents as a
formidable adversary against any sort of therapy.
While Woglom’s declaration was perhaps true in 1929, eight
decades of experimentation has yielded a more promising outlook.
Present attitudes toward immunotherapy are best described as
heterogenous: the field has been characterized as everything from
premature to blossoming. On one hand, the approval of immuno-
therapies such as IL-2, rituximab, ipilumimab, and sipuleucel-T
(Provenge) is testament to a level of acceptance of immunotherapy
for oncological treatment. Nevertheless, definitive efficacy and
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compelling effectiveness of broader applicability for such therapies
has yet to be demonstrated. In any case, where immunotherapy is
reported to be effective experimentally, the results have not been
translated to success in the clinic.
David Weiss argued in 1980 that the failure of clinical
immunotherapy is due not to categorical difference between
human and animal cancers, but rather that an irrelevant
laboratory tumor model was extrapolated for clinical application.
5
Similar assertions continue to be made, but have yet to be
substantiated by systematic analysis of the literature. Ultimately,
good experimental models of cancer are designed to represent as
closely as possible clinical cancers with the hope to mimic a
clinical setting. Here we analyze systematically the effects of
experimental immunotherapies on tumors differing in size and
duration of growth and determine the relative efficacy of different
immunotherapies. We hope to highlight the strengths and
shortcomings of experimental tumor models with regards to their
clinical relevance and also shed light on the potential advances
that have been made in experimental cancer immunotherapy.
Results
Quantity of evidence. All searches were conducted on PubMed
using the keywords “immunotherapy” AND “cancer” for the years
2010 and 1980. Reviews, clinical trials, and case reports were
excluded by the search engine. Further selection criteria were
followed as described in the Materials and Methods. Two
different types of analyses were conducted. In the first type of
analysis encompassing the entire year of 1980 or 2010, we only
extracted data reporting tumor size and duration of growth at the
beginning of therapy for a general survey of experimental models.
The second type of analysis used those studies published in
April, June, or November of 2010, and in the entire year of
1980, as long as studies provided extractable data on tumor
growth and efficacy of the treatment. These three months of
2010 were chosen to represent about one fourth of the
publications for the year and ensure that quarterly publications
would be represented.
In the first type of analysis, a total of 282 publications were
retrieved by the search in 1980. Of this number, ten
publications reported usable tumor size related data. A total of
789 publications were retrieved by the search in 2010. Of this
number, 195 publications reported experiments using solid
tumors and presented usable data on tumor growth. In the
second, more detailed analysis, 99, 100, and 90 publications
were retrieved for the months of April, June, and November
2010, respectively. Of these, 32, 26, and 16 publications
reported extractable growth data for the same respective months.
The size of tumors at the beginning of therapy. We
estimated an average tumor size at the beginning of therapy for
all experiments reported in 2010 (195 publications). Figure1
shows the size distribution of tumors employed in experimental
immunotherapies reported in 2010. In the bulk of publications,
tumors are treated ranging in volume between 0.5–121 mm
3.
The median reported tumor volume was 45 mm
3. The number
of publications falls off extremely rapidly with increasing tumor
size. The incidence of publications becomes sparse for tumor
volumes upwards of 375 mm
3.
The starting time of treatment after tumor cell inoculation.
From the 195 publications reporting size data in 2010, we
extracted the time given for tumors to establish before treatment
was given. Xenotransplanted tumors were excluded only from
this particular analysis due to the irregular growth kinetics of
xenografts in immunocompromised hosts. After excluding
xenotransplants, 158 publications reported the time when
treatment was given after tumor cell inoculation. The distribution
of times given for tumors to grow before treatment is presented
Figure2. The median time was 5 d. The bulk of publications
cluster around tumors that have grown for 4–8 d before
treatment. Only 15 publications reported tumors that had grown
for 14 d or longer before treatment.
The predominant effect of cancer immunotherapies is slowed
or delayed outgrowth. Having characterized the distribution of
tumor sizes employed in experimental immunotherapies, we asked
what sort of therapeutic effect could be achieved on these tumors
of varying sizes. The magnitude of the effect size (E) was expressed
as a ratio of linearized growth rates of treated tumors against
control tumors (Eqn. 1) (see Materials and Methods). The
subset of publications from 2010 reporting therapeutically related
experiments was used for detailed analyses. Equation 1 was
applied to these experiments reported in 74 papers from April,
June and November 2010, and the maximum effect size of
multiple reported experiments for each respective paper was
selected to represent that paper. In Figure3, the effect size on
tumor growth is plotted against tumor volume at the start of
treatment. Despite the prevalence of experiments using small
tumors, most succeed only at slowing or delaying tumor growth
Figure1. Precipitous falloff in the number of publications in the year 2010
with increasing size of tumors treated by immunotherapy. A search of
PubMed using the keywords “immunotherapy” AND “cancer” recovered
195 experimental studies that met our selection criteria. 75% of tumors
treated in these studies were smaller than 121 mm
3. Note the sparseness
of publications presenting tumors larger than 375 mm
3. (n = 195; Q1 = 0.5,
Q2 = 45, Q3 = 121.4)
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(0 , E # 1). By contrast, of the four experiments using large
tumors reported during these three months, two induce tumor
regression (E . 1), and one arrests tumor growth (E = 1).
Although the number of publications using large tumors is too
few to draw definitive conclusions, we note that the therapies that
induce regression of large tumors both use adoptive immune cell
transfer. Other types of immunotherapy do not seem to follow a
trend, and their effects are generally scattered.
Twelve out of 74 publications reported tumor regression. Ten
of these 12 used tumors smaller than 500 mm
3 at the beginning of
therapy, and eight used tumors less than 200 mm
3. Only two
papers reported regression of tumors larger than 500 mm
3. We
also examined the effectiveness of immunotherapies reported in
the entire year of 1980. Only ten publications reported analyzable
tumor growth data, all of which employed tumors less than
~100 mm
3 in size. None of the publications retrieved from 1980
reported tumor regression (E . 1, Fig.3, left panel).
Comparing the data from both years, an enormous difference
in the quantity of analyzable data is clear; in the three months of
2010 alone, there were more than seven times the number of
publications from the entire year of 1980 that presented
analyzable data. Both sets of data appear cluster around small
tumors less than 200 mm
3 in volume at the time of treatment
(Fig.3). However, a critical difference between the two is that the
scatter of the 2010 data reaches in the vertical direction toward
effect sizes greater than one, indicative of tumor regression.
Furthermore, the 2010 data also includes publications using larger
tumors, some of which even regress. Neither of these features is
present in the 1980 data.
The efficacy of immunotherapy against large tumors. The
paucity of experimentation using large tumors cannot yield
definitive conclusions for the effectiveness of immunotherapies.
We therefore proceeded to examine all experiments using large
tumors in 2010. While the standard size for an established
tumor is a 1 cm diameter or 500 mm
3 as discussed, a
400 mm
3 cutoff was selected to accommodate for a
reasonable amount of measurement and unit conversion
error (see Materials and Methods). As a further justification
for this cutoff, we observed a break in continuity between
375–425 mm
3 in the distribution of tumor sizes (Fig.1), so
no publication would be included at the expense of another
using similarly sized tumors. In 195 publications reporting
tumor size data for the year 2010, 13 were found to use
tumors with a volume greater than 400 mm
3.
7-19
Table 1 summarizes the reported experimental immu-
notherapies against large tumors retrieved in the year 2010
by our search. Of these 13 publications, nine reported tumor
regression or eradication
8,9,12,13,15-19 and four reported
slowed, delayed, or arrested growth.
7,10,11,14 The four demon-
strating arrested growth, employed passive antibody therapy
(Rituximab), adjuvant therapy (IL-1 receptor agonist, TLR-2
agonist), or dendritic cell vaccination. Six of the nine
publications demonstrating regression used adoptive cell
transfer therapy. Of the other three, one employed passive
antibody therapy (Rituximab), one used radioimmunother-
apy (
90Y-Veltuzumab), and the last transferred sporulating
C. novyi intravenously. Three publications reported eradication
and of these, animals were monitored for relapse for 0, 15 and
126 d. In the nine publications reporting tumor regression, five
used syngeneic tumors and three used human xenotransplanted
tumors in immunodeficient hosts.
Discussion
It is frequently claimed that the success of immunotherapy in
experimental animal models does not translate to success in the
clinic. A survey of the literature reveals that this discrepancy may
be attributed to inappropriate experimental design and general
indifference toward therapeutic goals of tumor rejection. The vast
majority of experimental immunotherapies target very small tumors
in mice, and the results are generally not applicable to tumors of
clinically detectable size. Experimental models which test therapy
when tumors are 0.5–120 mm
3 in volume or have only grown for
0–8 d measure the effect of therapy primarily against inflam-
matory swelling and few viable cancer cells;
4 unfortunately this
has been the case over decades of experimentation.
4,5,20,21 Further-
more, one would expect that successful therapy against these
small tumors would be reported often. Yet even when such small
tumors are being treated, the best effect is most frequently
described as a delayed or slowed growth rate. Size reduction of
a tumor is infrequently reported. A weak in vivo “anti-tumor
effect” against a small tumor may be helpful in understanding a
certain treatment regimen, and may also help the field of immu-
notherapy to progress; but it is not sufficient cause to celebrate an
experimental triumph, which has been all too frequent for a
majority of the papers coming from good laboratories and
reported in excellent journals and often touted by the lay press.
We cannot deny that moderate effects against small tumors
may hold potential relevance. Adjuvant immunotherapy is used
Figure2. Most experimental tumors are treated less than a week after tumor
cell inoculation. The median time reported was five days. All 158 cancer
immunotherapy studies listed in PubMed meeting our selection criteria for
2010 using syngeneic murine tumor models are presented. Only nine tumors
have grown for 14 d or longer before treatment. (n = 158; Q1 = 4, Q2 = 5,
Q3 = 8)
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micrometastases.
20 The significance of immunotherapy against
this sort of “secondary” disease should not be neglected, yet the
disproportionate amount of data concerned with minimally
detectable tumors raises a troubling question: Why isn’t there
much greater emphasis by investigators, funding agencies, and
journals on using experimental models more relevant to a frequent
clinical situation?
It is odd that even of the many publications treating small
tumors, few succeed in inducing regression. It seems that there is a
misguided attitude that any effect against tumor cells placed in a
mouse constitutes a noteworthy clinically interesting result.
Perhaps this discrepancy is symptomatic of misinterpreting the
purpose and outcome of an assay. Henry Winn, in 1960,
described an assay in which suspensions of lymph node cells and
tumor cells at varying ratios were injected into mice, and the
outgrowth of tumors was taken as a readout.
22 Variations of the
Winn assay are employed ubiquitously, but the interpretations of
results are misappropriated. Winn himself described the assay as
“a technique for assaying the activity of immunologically activated
lymphoid cells”,
22 and not as a readout for therapeutic potential.
A handful of publications today reporting Winn-like experiments
acknowledge the original purpose of the assay, and instead
immediately propose prospective therapeutic potential. Merely
performing a cytotoxicity assay in a mouse surrogate is a
doppelgänger compared with a rejection assay using a large
established tumor.
Despite the prevalence of inappropriate experimental models
and weak therapeutic effects, the field has certainly progressed.
Our search retrieved about a third as many publications in 1980
compared with 2010. Among these, very few publications
reported data sufficiently well to permit comparison and
replication. Many of the 1980 studies were more interested in
the nature of transplantation immunology, rather than cancer
immunotherapy. Of the therapeutically-related publications that
were excluded, many had insufficient controls or did not report
critical values necessary to generate a measure of effect size (E).
The tremendous expansion in accessibly reported data is a
testament to quality methodological standards and translational
ambitions. It should be noted the standard of reporting
experimental therapies remains erratic and compares poorly to
the conventions of clinical studies. Nevertheless, a few well-crafted
and well-reported studies have emerged in this examination of the
literature.
Despite the described failures of experimental cancer immu-
notherapy, cynicism is truly unwarranted. While all the
experimental immunotherapies reported three decades ago proved
to be ineffective and implemented minimally relevant tumors, a
number of studies from 2010 effectively induced regression of
large established disease. Thirteen publications are acknowledged
for employing large tumors, and of these 13, nine demonstrated
tumor regression, but not eradication to zero volume. Of the four
that did not induce regression, one induced a state of stable
disease and three accomplished slowed or delayed growth. The
Figure3. Most experimental immunotherapies published treat small tumors yet succeed only at slowing or delaying tumor growth, but in several recent
reports, larger tumors are being treated and a few reports present tumor regression. An effect size (E) of 1 indicates the treatment arrested tumor growth.
An E , 1 indicates that the treated tumor still grew progressively, but only slower than the control or in a delayed fashion, i.e., a reduction of the growth
rate of the tumor. An E . 1 indicates tumor regression. (Left panel) Detailed analysis was done for all experimental cancer immunotherapy publications
listed in PubMed for April, June, and November of 2010. Regression of tumors larger than 200 mm
3 is observed only after passive antibody or adoptive T
cell therapy. (n = 74). (Right panel) The same analysis was performed for those publications in the entire year of 1980. Very few publications presented
analyzable data. No publication uses tumors larger than 200 mm
3, and regression is not observed at all. (n = 10).
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latter three treated tumors by the administration of adjuvant,
cytokines, or vaccination—all of which constitute active immu-
notherapy. The former study used Rituximab to arrest tumor
growth. Of the nine publications reporting tumor regression,
eight employed some form of adoptive or passive immunotherapy
and one used intravenous delivery of C. novyi spores. Although
this study reported tumor regression within hours, the toxicity of
the therapy killed all animals within 24 h. Two studies employed
passive antibody therapy, one with a bacterial adjuvant, and one
conjugated to yttrium radioisotope. The remaining six studies
employed adoptive immune cell transfer.
The success of passive antibody or adoptive T cell immu-
notherapy compared with active immunotherapy against large
tumors speaks for itself. But this is not to say that active
immunotherapy should be abandoned—the fact that such
therapies have any effect on such large tumors is a success that
few other studies have even attempted to report. In combination
with passive antibody or adoptive T cell immunotherapy, the
therapeutic potential of adjuvants, cytokines, and vaccinations is
relatively untapped. Indeed, one study using adoptive cell transfer
required the additional support of cytokine expression to achieve
tumor regression. Undeniably, the heterogenous nature of cancer
will necessarily preclude any single immunotherapy from
becoming an archetype for therapeutic efficacy.
23
Our study is not intended to forecast either the efficacy of
cancer immunotherapy or the relevance of future studies to
clinical disease; rather, it is intended to describe the field as it
stands today. Our ambition is to bring attention to the current
trends in experimental cancer immunotherapy in a manner
substantiated by systematic analysis of the literature. For the
future, we aspire to witness finer experimental models and
superior therapeutic effects, with the hope of finding for patients
cancer immunotherapies that are also widely effective against
larger and longer established tumors.
Materials and Methods
Search and selection criteria. We conducted all searches of
PubMed using the keywords “immunotherapy” AND “cancer.”
All studies available via the University of Chicago Library were
inspected. Very few studies were unavailable for inspection.
Studies were limited to those in mice carrying syngeneic,
allogeneic, or xenogeneic tumors. All tumor types were included
in each of our analyses, with the exception of the analysis
concerning the duration of tumor growth before the start of
treatment. Xenotransplants were excluded from this particular
analysis due to the irregular growth kinetics of xenograft tumors
in immunocompromised mice. One study used autochthonous
Table1. Effects and types of experimental immunotherapies reported in the year 2010 treating tumors . 400 mm
3 in size
Author Tumor model Type of immunotherapy Size of tumor and duration of
growth at start of treatment*
Strongest reported
treatment effect
Sharkey RM, et al.
15 xenotransplant
(Ramos)
radioimmunotherapy
90Y-Veltuzumab
0.5 cm
3
(time not reported)
rejection in 9/10 mice
(monitored 18 wks post-
rejection, 1 relapse at wk 7)
Maletzki K, et al.
19 syngeneic
(Panc02)
adjuvant
bacteriolytic C. novyi
450 mm
3
(32 d)
0m m
3 (monitored 15 d
post-rejection)
Garcia-Hernandez
Mde L, et al.
9
syngeneic
(B16-OVA)
adoptive transfer
Tc17 T cells
500 mm
3
(7 d)
rejection, no long-term
growth data
Paulos CM, et al.
13 xenotransplant
(M108)
adoptive transfer
Th17 cells
190 mm
2
(6–7 weeks)
regression to 50 mm
2
Kerkar S, et al.
12 syngeneic
(B16)
adoptive transfer
IL-12 engineered pmel-1 CD8
+
80–100 mm
2
(14 d)
regression 10 mm
2
Xie Y, et al.
17 syngeneic
(B16)
adoptive transfer
TRP-1 CD4
+
100 mm
2
(11 d)
regression 16 cm
2
Zhao Y, et al.
18 xenotransplant
(M108)
adoptive transfer
RNA CAR T cells
100 mm
2
(66 d)
regression 50 mm
2
Shrimali RK, et al.
16 syngeneic
(B16)
adoptive transfer, antibody
pmel splenocytes, anti-VEGF
100–200 mm
2
(12–18 d)
regression to 10 mm
2
then relapse
Buhé V, et al.
8 xenotransplant
(Daudi)
antibody, adjuvant
Rituximab + CpG
0.94 cm
3
(35 d)
regression 0.51 cm
3
Ringshausen I, et al.
14 xenotransplant
(SUDHL4)
antibody
rituximab
100 mm
2
(time not reported)
no change in volume
Kayashima H, et al.
11 syngeneic
(MH134)
Cytokine and vaccination
IL-12 and DC vaccination
0.5 cm
3
(time not reported)
growth delay
Harnack U, et al.
10 syngeneic
(CT26)
adjuvant
IL-1 receptor agonist
440 mm
3
(8 d)
growth delay
Akazawa T, et al.
7 syngeneic
(EL4-EG7)
adjuvant
synthetic TLR-2 agonist
1.4–1.6 cm
3
(16 d)
growth delay
*Sizes are listed as reported. The 13 publications listed had sizes that converted to 400 mm
3 or larger.
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carcinogen-induced tumors and was excluded because it was
impossible to determine how much the carcinogen contributed
to inflammation. Studies were also limited to those written in
English. Relevance was first determined by inspection of the title
and abstract, followed by more detailed reading when necessary.
Prophylactic therapies, including vaccinations and other treat-
ments administered before tumor cell inoculation were excluded.
Prophylaxis is very different from therapy of established disease,
be it cancer or the flu.
6 The immunological factors that contribute
to this distinction are innumerable (tolerance, suppression, tumor
microenvironment, etc.). Prophylactic immunotherapies are
capable of producing very impressive successes, but we are
concerned here with models which mimic patients in the clinic
with preexisting tumors.
Describing tumor size. The effects of therapies were reported
either in terms of solid tumor growth or animal survival over time.
Survival data were excluded because surrogate endpoints were
inconsistent. We expressed changes in size of tumors as an index
of the experimental effect on growth relative to control (Eqn. 1).
Relevant values were taken from the text as reported or otherwise
inspected visually. We describe tumor size as a volume V = 1/2
(a   b   c), where a, b and c are orthogonal diameters.
24-26 In
some cases, volume was expressed as the product of the square of
the major diameter times the minor diameter divided by two.
Tumor sizes expressed in two dimensions as area were generally
reported as the product of orthogonal diameters. The square root
of the area was taken as the geometric mean of diameters, and
used as an average diameter for calculating volume as described
above. For tumor sizes reported in one dimension, the reported
diameter was used accordingly. Tumors described as “palpable” or
“detectable” were interpreted as 1 mm in diameter. Tumors
characterized by mass were converted to volumes assuming a
1 g/cm
3 tumor density; since mass is directly proportional to
volume, our description effect size is not biased by this trans-
formation. Although different methods of measurement were
employed across the publications, the normalization of the effect
of treatment on tumor growth compared with control tumor
growth minimizes potential discrepancy.
Describing the effects of immunotherapy (“effect size” E). We
sought to formulate a measure of effect size of treatment on the
growth of tumors. This effect size was expressed as a ratio of
linearized growth rates of treated tumors against control tumors
(Eqn. 1). The tumor growth rate of each group was determined
using the tumor size at the time that treatment was given to the
experimental group (Vi and ti) and the tumor size at the endpoint
for each respective group (Vf and tf).
E
Rate
Rate
Rate
VV
tt
treated
control
fi
fi
   


1  where   1 
Untreated mice were used for controls when available.
Otherwise, mock treatments or vehicles were used as control
(phosphate-buffered saline, saline, normal immunoglobulin, etc.).
In principle, we required controls that were designed to have a
minimal effect on tumor growth.
A more sophisticated logistic or Gompertzian growth model
might better suited to describe tumor growth; however,
the reported data is usually insufficient for the application of
such models. Our objective was to produce a usable measure
of the effect of treatment on the behavior of tumor growth
that could be applied across a wide strata of data. Since the
effect is expressed relative to the control growth rate, our
measure is sufficient to assign an effect size to any controlled
experiment.
A qualitative interpretation of our effect size can be derived
computationally. All of the following interpretations assume that
the control tumor grows out and does not spontaneously regress;
this was true for all collected data. An effect size less than zero
indicates that the treated tumor grows out faster than the control.
An effect size of zero indicates that the treated tumor had the same
growth behavior as the control. For an effect size between zero
and one, the treated tumor grows out, but either is slowed or
delayed compared with the control. An effect size equal to one
indicates stable disease. An effect size greater than one indicates
regression of the treated tumor.
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